Skip to Main Content

When It Comes to RSV, You Call the Shots

Date: 12/28/23

Your patients trust you more than any other source when it comes to vaccines. And your recommendation is the most effective way to ensure they get the ones they need.

RSV is the leading cause of childhood respiratory illness in the United States, resulting in thousands of hospitalizations and hundreds of deaths per year. Two FDA approved, and CDC recommended solutions can help protect the communities you serve from severe respiratory syncytial virus (RSV).

For the 2023-2024 RSV season, there are known supply shortages of the infant RSV Monoclonal Antibody Nirsevimab. In areas with shortages, guidance is to encourage maternal RSV vaccination as an alternative.

Infant RSV Monoclonal Antibody (Nirsevimab)

  • A single intramuscular injection for infants younger than 8 months of age born during or entering into their first RSV season to prevent severe RSV disease.

Maternal RSV Vaccination (Abrysvo)

Pfizer’s bivalent RSVpreF vaccine, Abrysvo is the only RSV vaccine approved for use during pregnancy.

  • A single injection given to pregnant individuals at 32 weeks through 36 weeks gestational age have shown reduction in severe RSV infection in infants by 81% within 90 days of life, and 69% within 180 days of life.
  • Provides protection for infant if maternal vaccination occurred at least 14 days prior to birth.

Thank you for being a trusted partner in the healthcare decisions of those you care for.

Download our flyer (PDF) for additional information and resources for your use.

If you have questions about this bulletin or other provider resources, please contact your Provider Relations Representative call us at the numbers below.